SOPHiA GENETICS™

SOPHiA DDM™ Insights

Transform your precision medicine journey

Identify unmet medical needs and underserved patient groups early on your precision medicine journey. Shorten drug development timelines and reduce costs by leveraging SOPHiA DDM™ Platform to unlock biologically actionable insights from genomic and molecular epidemiology profiles, geographical distribution, and routine genetic testing practices.

New medicines take

10+

years to be tested and approved[1]

Patient Group Selection

Understand the size and geographical distribution of your **target populations** and identify patient subgroups based on biomarker and molecular profiles

Biomarker Identification

Unveil **co-occurring** and **mutually exclusive** mutation patterns across diverse patient groups

Molecular Epidemiology Insights

Unveil the genetic alterations associated with **disease** at the population level

Benefits of SOPHiA DDM™ Insights

- De-risk and expedite your clinical development process by identifying the **right targets for drug development**
- Eliminate the guesswork by accessing **real-life** data from diverse patient populations early in your journey
- Accelerate enrollment by exploring real-time data from a vast **clinical research network** spread across 750+ institutions

1. Marchetti S. and Schellens J. H. M. 2007. Br J Cancer. 97(5):577-581. doi: 10.1038/sj.bjc.6603925

Accelerate drug development with SOPHiA DDM™ Insights

Identify the genomic **biomarker** of interest

Run a **retrospective** study on SOPHiA DDM™

Run a deeper **epidemiology analysis** on SOPHiA DDM™

Define the **geographic** scope of interest

Generate a statistical data insights report

CASE STUDY

SOPHiA DDM™ Insights Enables the Epidemiologic Study of MET Exon 14 Skipping

MET alterations are an attractive clinical target in human cancers. However, multiple aspects of its molecular epidemiology remain challenging, particularly the interpretation of variants leading to exon skipping events[2].

Key outcomes

1. SOPHiA DDM™ Insights allowed the accurate detection of *MET* alterations and exon skipping events at the DNA and RNA level.
2. In Europe, **3.2% of cancer patients** tested positive for *MET* variants that could lead to ex14 skipping.
3. About **25% of *MET*ex14dels** co-occurred with alterations in other lung cancer-associated genes[3].

2. Frampton G. M. et al. 2015. Cancer Discov. 5(8):850-859. doi: 10.1158/2159-8290.CD-15-0285
3. Wolf J. et al. 2021. Ann. Oncol. 32(5):S400. doi:10.1016/j.annonc.2021.08.381.

MET testing footprint in Europe



*MET*ex14 co-occurrence with other oncogenes



About SOPHiA GENETICS

750+ Healthcare Institutions

70+ Countries

1 Million+ Genomic Profiles

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ platform and related solutions, products and services were used by more than 750 hospitals, laboratories, and biopharma institutions globally in 2021.

Want to learn more?

Or contact us at:
info@sophiagenetics.com